Cargando…

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA) on the PK of the immune checkpoint inhibitor atezolizumab (a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Benjamin, Sternheim, Nitzan, Agarwal, Priya, Suchomel, Julia, Vadhavkar, Shweta, Bruno, Rene, Ballinger, Marcus, Bernaards, Coen A., Chan, Phyllis, Ruppel, Jane, Jin, Jin, Girish, Sandhya, Joshi, Amita, Quarmby, Valerie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742635/ https://www.ncbi.nlm.nih.gov/pubmed/34432389 http://dx.doi.org/10.1111/cts.13127

Ejemplares similares

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
por: Hammer, Christian, et al.
Publicado: (2022)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

notch3 is essential for oligodendrocyte development and vascular integrity in zebrafish
por: Zaucker, Andreas, et al.
Publicado: (2013)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins
por: Kierzek, Andrzej M., et al.
Publicado: (2019)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
por: Sothornwit, Jin, et al.
Publicado: (2019)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
por: Li, Chunze, et al.
Publicado: (2019)

Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product
por: Vanderlaan, Martin, et al.
Publicado: (2019)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2022)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
por: Kassir, Nastya, et al.
Publicado: (2023)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
por: Nwanwene, Kemnasom, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals
por: Ekinci, Meliha, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
por: Kotani, Naoki, et al.
Publicado: (2022)

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
por: Fehlings, Michael, et al.
Publicado: (2019)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
por: Fa’ak, Faisal, et al.
Publicado: (2019)

Atezolizumab-induced bilateral anterior uveitis: A case report
por: Mito, Tsuyoshi, et al.
Publicado: (2021)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab
por: Benjamin, Lardinois, et al.
Publicado: (2021)

Atezolizumab: Drug-induced immune haemolytic anaemia: case report
Publicado: (2022)

Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
por: Patel, Hina, et al.
Publicado: (2021)

Electrolyte Abnormalities Associated With the Use of Atezolizumab – A Systematic Review
por: Rafae, Abdul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ei2kvaqs5tofn1d556758ftd1f